Browse studies

Find your next paid study

62 recruiting studies matching your filters

A Randomized Placebo-procedure Controlled Trial of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System PULmonary Artery Denervation Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiof…

Pulmonary HypertensionHeart Failure With Reduced Ejection FractionHypertension+5 more

Estimated

~$10 – $8,750

Pulnovo Medical, Inc.NCT07214376

A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension

Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH a…

Pulmonary DiseasePulmonary Hypertension

Estimated

~$10 – $675

National Institutes of Health Clinical Center (CC)NCT01730092

Pulmonary Hypertension (PH) Biorepository for Translational Research

Background: Pulmonary hypertension (PH) is high blood pressure in the blood vessels of the lungs. It can lead to heart failure and death if not treated. Resea…

Pulmonary Hypertension

Estimated

~$10 – $675

National Institutes of Health Clinical Center (CC)NCT07647549

Phase 1

Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fr…

Pulmonary HypertensionHeart Failure With Preserved Ejection Fraction

Estimated

~$10 – $8,750

35Pharma IncNCT07123779

Phase 2

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension …

Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Estimated

~$10 – $8,750

OrphAI TherapeuticsNCT05798923

Phase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with …

Pulmonary HypertensionInterstitial Lung Disease

Estimated

~$10 – $8,750

Insmed IncorporatedNCT07179380

Phase 1

Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension: A Prospective Open-Label Matched Control Pilot Trial.

This prospective open-label matched-control pilot study evaluates whether inhaled treprostinil improves exercise pulmonary vascular resistance and functional o…

Pulmonary Hypertension

Estimated

~$10 – $6,250

Valley Health SystemNCT07837830

Phase 1

A Phase 2a Single Arm Open Label Safety and Efficacy Study of Telaglenastat Plus Standard of Care in Adults With Functional Class Ii-iii Precapillary Pulmonary Hypertension Across Wsph Groups 1-3

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is …

Pulmonary Hypertension

Estimated

~$10 – $7,500

Chan, Stephen, MD, PhDNCT07223528

Phase 3

A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmo…

Pulmonary HypertensionInterstitial Lung DiseaseVascular Diseases+2 more

Estimated

~$10 – $8,750

Pulmovant, Inc.NCT07816185

Phase 3

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)

The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by inters…

Pulmonary Hypertension Due to Lung Disease (Disorder)

Estimated

~$10 – $8,750

Liquidia Technologies, Inc.NCT07285655

Phase 2

An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypert…

Pulmonary HypertensionInterstitial Lung Disease (ILD)Lung Diseases+3 more

Estimated

~$10 – $8,750

Pulmovant, Inc.NCT07333183

Observational

MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion)

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with intersti…

Pulmonary HypertensionInterstitial Lung Disease (ILD)

Estimated

~$10 – $7,500

Tempus AINCT06911632